by According to a research report “Head and Neck Cancer Drugs Market (By Treatment Type: Chemotherapy, Radiation Therapy, Targeted Therapy, and Immunotherapy; By Sales Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030″ published by Precedence Research, the head and neck cancer drugs market is projected to grow from USD 1.62 billion in 2022 and is forecasted to reach USD 2.99 billion by 2030; it is expected to grow at a CAGR of 7.9% from 2022 to 2030.
The study provides an analysis of the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
The rising prevalence of head and neck cancer across the globe is the primary factor behind the growth of the global head and neck cancer drugs market. According to the World Health Organization, over 550,000 cases of head and neck cancer and around 300,000 associated deaths are recorded annually across the globe. It is known as the sixth leading type of cancer based on incidence.
Get a Free Sample Copy of this Report with Global Industry Analysis @ https://www.precedenceresearch.com/sample/1474
The rising consumption of alcohol and tobacco is a major factor behind the occurrence of the head and neck cancer. The rising investments by the pharmaceutical companies in the development of various innovative therapies such as targeted therapy, immunotherapy, and biosimilar are the significant driving forces. The rising awareness among the population regarding the head and neck cancer and the various drugs to cure head and neck cancer is boosting the growth of the market. The easy availability and access to advanced healthcare facilities have propelled the demand for the various head and neck cancer drugs across the globe.
Table of Contents
Head and Neck Cancer Drugs Market Estimations Y-O-Y:
- Market Size Was Valued In 2021: US$ 1.51 Billion
- Market Size Is Projected to Grow By 2022: US$ 1.62 Billion
- Market Size Is Projected to Grow By 2023: US$ 1.75 Billion
- Market Size Is Projected to Grow By 2024: US$ 1.88 Billion
- Market Size Is Projected to Grow By 2025: US$ 2.03 Billion
- Market Size Is Projected to Grow By 2026: US$ 2.19 Billion
- Market Size Is Projected to Grow By 2027: US$ 2.37 Billion
- Market Size Is Projected to Grow By 2028: US$ 2.56 Billion
- Market Size Is Projected to Grow By 2029: US$ 2.76 Billion
- Market Size Is Projected to Grow By 2030: US$ 2.99 Billion
- Compound Annual Growth Rate (CAGR) from 2022 to 2030: 7.9 percent
Scope of the Head and Neck Cancer Drugs Market
| Report Highlights | Details |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | Treatment, Sales Channel, Region |
Market Dynamics
Driver
Rising popularity of the immunotherapy
The demand for the immunotherapy is rising among the head and neck cancer patients, owing to the increasing awareness regarding the benefits of the immunotherapy drugs over the traditional chemotherapy. Chemotherapy involves various risks such as reoccurrence of cancer, high side-effects, loss of life, and organ failure. The immunotherapy has no or low side-effects and provides effective treatment. This is boosting the demand for the immunotherapy drugs among the patients across the globe.
Restraint
Side-effects associated with the chemotherapy
Head and neck cancer id often treated using the combination of chemotherapy and radiation therapy. The various side-effects involves hair loss, faulty speech, and loss of normal voice. Moreover, the patients face difficulties in eating food after the cancer surgery. These inconveniences associated with the treatment are expected to hinder the market growth during the forecast period.
Opportunities
Rising adoption of latest technologies in the drug development
The manufacturers are adopting latest technologies like AI and data analytics for the research and production of various immunotherapy drugs, target therapy drugs, and biosimilar. The enhanced production and improved quality is expected to provide growth aspects to the market players in the forthcoming future.
Challenges
Lack of healthcare facilities
The developing and the underdeveloped countries lacks in adequate healthcare infrastructure that deprives the population from acquiring basic healthcare services. Moreover, weak economic conditions of the people decrease the affordability of the expensive head and neck cancer drugs.
Read Also: Automotive Interior Market 2030 Potential Opportunity Is Opening in the Coming Years
Report Highlights
- Based on the treatment type, the chemotherapy dominated the global head and neck cancer drugs market in 2020. Chemotherapy is extensively used with the other therapies like radiation therapy in combination for the treatment of the head and neck cancer. This has resulted in the dominance of this segment. Moreover, the rising incidences of the head and neck cancer across the globe are further expected to drive the growth of the market.
- Based on the sales channel, the online pharmacies segment is estimated to be the most opportunistic segment during the forecast period. This is attributable to the rising popularity of various online pharmacy retail platforms across the globe. Moreover, the rising adoption of smartphones coupled with improved access to the internet is positively impacting the market growth. More than half of the global population had access to internet by the end of 2019, as per the ITU. This number is expected to grow rapidly in the foreseeable future, which in turn would impact the market growth significantly.
Regional Snapshot
North America accounted for the largest market share of the global head and neck cancer drugs market in 2020. The enhanced access to the healthcare services and advanced diagnostic services has resulted in the early screening of the head and neck cancer in North America. Moreover the increased consumption of tobacco, alcohol, and smoking has resulted in the rising incidences of head and neck cancer. According to the American Cancer Society, head and neck cancer accounts for around 4% of the total cancer cases in US.
In 2021, it is estimated that around 48,740 men and 17,890 women will develop head and neck cancer. Around 14,620 deaths are estimated to occur in US in 2021 due to head and neck cancer. This is a major factor that spurs the demand for the head and neck cancer drugs across North America.
Asia Pacific is expected to be the fastest-growing market during the forecast. This is attributable to the rising investments in the development of advanced healthcare infrastructure for improving the access to the healthcare services is exponentially driving the market growth. The rising awareness regarding the head and neck cancer coupled with rising healthcare expenditure and rising adoption of healthcare insurances in the region is driving the growth of the head and neck cancer in Asia Pacific.
Why should you invest in this report?
If you are aiming to enter the global head and neck cancer drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for head and neck cancer drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Head and Neck Cancer Drugs Market
5.1. COVID-19 Landscape: Head and Neck Cancer Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Head and Neck Cancer Drugs Market, By Treatment
8.1. Head and Neck Cancer Drugs Market, by Treatment Type, 2021-2030
8.1.1. Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Chemotherapy
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Radiation Therapy
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Immunotherapy
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Head and Neck Cancer Drugs Market, By Sales Channel
9.1. Head and Neck Cancer Drugs Market, by Sales Channel, 2021-2030
9.1.1. Retail Pharmacies
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Hospital Pharmacies
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Head and Neck Cancer Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
Chapter 11. Company Profiles
11.1. AstraZeneca PLC
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bristol-Myers Squibb Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Eli Lilly and Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Fortress Biotech, Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Immutep Limited
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Merck & Co., Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Merck KGaA
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novartis AG
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pfizer Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1474
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
